Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Autor: Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González-Martín

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)

Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access

Externí odkaz: https://doaj.org/article/535064772afa48388b62acdd5418de2a

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.

Autor: Fernando Franco, Enric Carcereny, Maria Guirado, Ana L Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel Del Barco, Oscar Juan, Francisco Aparisi, Jose L González-Larriba, Manuel Domine, Jose M Trigo, Manuel Cobo, Sara Cerezo, Julia Calzas, Bartomeu Massutí, Joaquim Bosch-Barrera, Paola García Coves, Marta Domènech, Mariano Provencio

Publikováno v: PLoS ONE, Vol 16, Iss 6, p e0251761 (2021)

BackgroundSmall-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.P

Externí odkaz: https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Autor: Andrés Muñoz, Cihan Ay, Ella Grilz, Sonia López, Carme Font, Vanesa Pachón, Victoria Castellón, Virginia Martínez-Marín, Mercedes Salgado, Eva Martínez, Julia Calzas, Laura Ortega, Ana Rupérez, Eduardo Salas, Ingrid Pabinger, Jose Manuel Soria

Publikováno v: Journal of Clinical Oncology. 41:2911-2925

PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82b9ec49552f9a1f26aa98920ca5f9f8
https://doi.org/10.1200/jco.22.00255

Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO

Autor: Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, Maria Luisa Sanchez Lorenzo

Publikováno v: Journal of Clinical Oncology. 40:e17598-e17598

e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer (HGOC), and as treatment for BRCA-mutant HGOC patients. To date, there is little evidence about t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35357b7514f82b11ae213ede72dccbfa
https://doi.org/10.1200/jco.2022.40.16_suppl.e17598

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

Autor: Bartomeu Massuti, Paola García Coves, M. Guirado, Julia Calzas, Ana Ortega, R. López-Castro, Edel del Barco, Oscar Juan, Delvys Rodriguez-Abreu, Rosario García-Campelo, Jose Manuel Trigo, Francisco Aparisi, Enric Carcereny, Joaquim Bosch-Barrera, Mariano Provencio, Manuel Cobo, Fernando Faria Franco, José Luis González-Larriba, Manuel Domine, S. Cerezo, Marta Domenech

Publikováno v: PLoS One
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO. Repositorio Institucional de Producción Científica
PLoS ONE
PLoS ONE, Vol 16, Iss 6, p e0251761 (2021)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Plos One
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039ecc04c25bfa0317d46b151c664126
https://fundanet.fihgu.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1953